Twist Bioscience reported a strong second quarter with revenue increasing to $75.3 million, a 25% increase year-over-year, and orders increasing to $93.2 million, a 45% increase year-over-year. The company's gross margin improved to 41%, and they are focused on achieving profitability.
Total revenue increased to $75.3 million, up 25% compared to the same period last year.
Total orders increased to $93.2 million, up 45% compared to the same period last year.
Gross margin improved to 41% compared to 31% for the same period last year.
Net loss attributable to common stockholders was $45.5 million, or $0.79 per share, compared to $59.2 million, or $1.04 per share, for the same period last year.
Twist Bioscience updated its financial guidance for fiscal year 2024 and provided guidance for the third and fourth quarters of fiscal year 2024.
Visualization of income flow from segment revenue to net income